2024-03-07 22:22:17 ET
Lineage Cell Therapeutics, Inc. (LCTX)
Q4 2023 Earnings Conference Call
March 07, 2024, 04:30 PM ET
Company Participants
Ioana Hone - Head of IR
Brian Culley - CEO
Jill Howe - CFO
Conference Call Participants
Joe Pantginis - H.C Wainwright
Jack Allen - Baird
Kristen Kluska - Cantor Fitzgerald
Mayank Mamtani - B. Riley
Sean McCutcheon - Raymond James
Michael Okunewitch - Maxim Group
Presentation
Operator
Welcome to the Lineage Cell Therapeutics Fourth Quarter and Fiscal Year-End 2023 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investors section of Lineage's website at www.lineage.com. This call is subject to copyright and is the property of Lineage. And recordings for productions or transmissions of this call without the express written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded.
I would now like to introduce you to your host for today's call, Ioana Hone, Head of Investor Relations of Lineage. Ms. Hone, please go ahead.
Ioana Hone
Thank you, John. Good afternoon, and thank you for joining us. A press release reporting our fourth quarter and fiscal year 2023 financial results was issued earlier today, March 7, 2024, and can be found on the Investors section of our website.
Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by such forward-looking statements.
For a discussion of certain factors that could cause the company's results or performance to differ, we refer you to the forward-looking statements section in today's press release and in the company's SEC filings, including its annual report on Form 10-K, for the year ended December 31, 2023. We caution you not to place undue reliance on any forward-looking statements, which speak only as of today and are qualified by the cautionary statements and risk factors described in our SEC filings.
With us today are Brian Culley, our Chief Executive Officer; and Jill Howe, our Chief Financial Officer. Now let me turn the call over to Brian.
Brian Culley
Thank you, Ioana, and good afternoon, everyone. We appreciate you taking the time to join us today for a recap of 2023 and an update on some important items occurring in 2024. Over the past year, our team continued to focus on the advancement of our pipeline of differentiated cell transplants, while also providing support for our lead program, which is partnered with Roche and Genentech. We continue to have many reasons to be excited about our future....
Read the full article on Seeking Alpha
For further details see:
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2023 Earnings Call Transcript